npegRNA Design Innovation: Overcoming the Limitations of Prime Editing Efficiency
-
Limitations of Existing Technology: Unstable Structure Prime editing (Prime Editing) is a groundbreaking technology that can precisely correct genes, but it has a fatal flaw: the end of the pegRNA containing the correction information is easily broken down by cellular enzymes. This made it difficult to secure the efficiency required for actual treatment.
-
Innovative Design: The Emergence of npegRNA The research team developed a non-canonical pegRNA (npegRNA) by completely redesigning the structure of pegRNA. The key was to insert the exposed correction template (RTT-PBS) into the internal loop structure of the guide RNA. This protected structure has resistance to attack by cellular nucleases (Exonuclease), allowing it to survive for a longer period in the cell and perform editing work while bound to the Cas9 protein.
-
Overwhelming Performance Metrics npegRNA showed a remarkable increase in efficiency compared to existing methods.
- Compared to conventional canonical pegRNA: achieved an average of 26.8 times higher editing efficiency
- Compared to engineered epegRNA: achieved an average of 5.9 times higher editing efficiency
- Introduction of disease variants: improved efficiency by up to 123 times in induced pluripotent stem cells (iPSC) and other cells
- Proof of Therapeutic Potential and Future Value The research team applied this technology to a genetic tyrosinemia mouse model and successfully corrected the actual disease gene. This suggests that npegRNA technology can be a powerful and practical tool for treating intractable genetic diseases beyond the laboratory level. This study is expected to be an important stepping stone for elevating prime editing technology to the standard for next-generation gene therapy.
Prime editing (PE) enables precise genetic modifications using canonical prime editing guide RNA (pegRNA), with the reverse transcription template and primer binding site (RTT-PBS) attached to the 3' ends of CRISPR-Cas guide RNAs. Although PE ribonucleoprotein (RNP) delivery holds great therapeutic potential, its weak genomic editing capability limits therapeutic applications. Here we present structure-guided engineering of the PE complex using non-canonical pegRNAs (npegRNAs), with the RTT-PBS integrated within the single guide RNA loops, to improve PE efficiency. This approach demonstrates enhanced precise editing rates across various genomic sites and cell types, and improves therapeutic gene correction in a tyrosinaemia mouse model. Cas9-associated npegRNAs are more resistant to exonuclease degradation, probably enhancing the PE complex's targeting efficiency in living cells. Using PE RNP delivery, npegRNAs achieve increased average editing yields of 26.8-fold over canonical pegRNAs and 5.9-fold over engineered pegRNAs (epegRNAs). Furthermore, npegRNA-mediated RNPs increased the efficiency of installing disease-relevant mutations up to 123-fold in human cell lines, including Jurkat T cells and induced pluripotent stem cells. Collectively, our findings demonstrate a robust PE strategy and highlight the potential of npegRNAs for therapeutic PE applications.
If editing efficiency is greatly improved, accurate correction of genetic diseases becomes possible. Additionally, the scope of personalized gene therapy expands as it becomes applicable to various cell types.